Ronald Todd Plott Acquires 15,000 Shares of Phio Pharmaceuticals (NASDAQ:PHIO) Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Todd Plott purchased 15,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were purchased at an average price of $1.14 per share, with a total value of $17,100.00. Following the acquisition, the director directly owned 15,000 shares in the company, valued at $17,100. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Phio Pharmaceuticals Trading Down 2.5%

Shares of NASDAQ:PHIO opened at $1.18 on Friday. Phio Pharmaceuticals Corp. has a 52 week low of $0.81 and a 52 week high of $4.19. The company’s 50 day moving average is $1.04 and its two-hundred day moving average is $1.12. The company has a market cap of $13.71 million, a PE ratio of -0.91 and a beta of 0.82.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.36). As a group, equities research analysts expect that Phio Pharmaceuticals Corp. will post -1.41 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $14.00.

Hedge Funds Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Cetera Investment Advisers grew its stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,500 shares of the company’s stock after purchasing an additional 9,000 shares during the quarter. Cetera Investment Advisers owned approximately 0.39% of Phio Pharmaceuticals worth $45,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.